Alistair Ring
Overview
Explore the profile of Alistair Ring including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1684
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Murillas I, Cutts R, Walsh-Crestani G, Phillips E, Hrebien S, Dunne K, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(3):493-502.
PMID: 39424680
Purpose: Detection of molecular residual disease (MRD) allows for the identification of breast cancer patients at high-risk of recurrence, with the potential that early initiation of treatment at early stages...
2.
Coriano M, Tommasi C, Dinh A, Needham J, Aziz H, Joharatnam-Hogan N, et al.
Breast Cancer Res Treat
. 2024 May;
206(3):603-614.
PMID: 38743174
Purpose: Many patients with early breast cancer (eBC) undergoing neoadjuvant chemotherapy do not achieve pathological complete response (pCR), which is a prognostic factor. We examined the role of HER2-low expression...
3.
Senechal I, Andres M, Tong J, Perone Y, Ramalingam S, Nazir M, et al.
Cardiooncology
. 2024 Mar;
10(1):14.
PMID: 38454509
Long-term anti-HER2 therapy in metastatic HER2 + cancers is increasing, but data about the incidence and risk factors for developing late Cancer therapy-related cardiac dysfunction (CTRCD) are missing. We conducted...
4.
Eochagain C, Barrell A, Slavova-Boneva V, Murphy J, Pattwell M, Cumming J, et al.
J Geriatr Oncol
. 2024 Jan;
15(2):101698.
PMID: 38219333
Introduction: Despite significant evidence supporting the benefits of comprehensive oncogeriatric assessment in the management of older patients with cancer, the adoption of specialised geriatric oncology programs in the United Kingdom...
5.
Kingston B, Pearson A, Herrera-Abreu M, Sim L, Cutts R, Shah H, et al.
Cancer Discov
. 2023 Nov;
14(2):274-289.
PMID: 37982575
Significance: Novel F404 ESR1 mutations may be acquired to cause overt resistance to fulvestrant when combined with preexisting activating ESR1 mutations. Novel combinations of mutations in the ER ligand binding...
6.
Eochagain C, Barrell A, Murphy J, Pattwell M, Cumming J, Slavova-Boneva V, et al.
J Geriatr Oncol
. 2023 Oct;
15(2):101641.
PMID: 37813781
No abstract available.
7.
Ring A, Karuturi M, Smyth E, Lokhandwala T, Sheffield K, Willey J, et al.
Drugs Real World Outcomes
. 2023 Sep;
10(4):589-603.
PMID: 37775689
Introduction: Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) is the most frequently diagnosed metastatic breast cancer (mBC) subtype. Combinations of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors...
8.
Ring A, Kilburn L, Pearson A, Moretti L, Afshari-Mehr A, Wardley A, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4751-4759.
PMID: 37773077
Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous...
9.
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, et al.
J Clin Oncol
. 2023 Aug;
41(33):5118-5130.
PMID: 37556775
Purpose: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of...
10.
Joharatnam-Hogan N, Hatem D, Cafferty F, Petrucci G, Cameron D, Ring A, et al.
Br J Cancer
. 2023 Jul;
129(4):706-720.
PMID: 37420000
Background: Pre-clinical models demonstrate that platelet activation is involved in the spread of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits platelet activation, can prevent or delay metastases....